Advertisement

45-Year-Old with Psoriasis Started on Adalimumab

  • Michael P. Lee
  • Kevin K. Wu
  • Jashin J. Wu
Chapter
Part of the Clinical Cases in Dermatology book series (CLIDADE)

Abstract

TNF-alpha response is also crucial in inhibiting viral replication along with aiding in viral clearance. There is an increased risk of hepatitis B with TNF-alpha inhibitors and patients should be screened for hepatitis B prior to initiating treatment. For patients with psoriasis and coexisting hepatitis B infection, phototherapy, ustekinumab, and interleukin-17 inhibitors may be considered. This is a case of a 45-year-old male with history of positive anti-HBc testing.

Keywords

Psoriasis Hepatitis B 

References

  1. 1.
    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85.  https://doi.org/10.1016/j.jaad.2009.03.027.CrossRefPubMedGoogle Scholar
  2. 2.
    Fotiadou C, Lazaridou E, Ioannides D. Safety of anti-tumour necrosis factor-alpha agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol. 2011;25(4):471–4.  https://doi.org/10.1111/j.1468-3083.2010.03754.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-alpha biological therapy: from bench to bedside. J Microbiol Immunol Infect. 2014;47(4):268–74.  https://doi.org/10.1016/j.jmii.2013.03.005.CrossRefPubMedGoogle Scholar
  4. 4.
    Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol. 1990;12(5):562–8.CrossRefGoogle Scholar
  5. 5.
    Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.  https://doi.org/10.1002/hep.29800.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 2016;20(4):607–28.  https://doi.org/10.1016/j.cld.2016.06.006.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S, Medical Board of the National Psoriasis Foundation. From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014;70(1):178–86.  https://doi.org/10.1016/j.jaad.2013.08.049.CrossRefPubMedGoogle Scholar
  8. 8.
    Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–9; quiz e216–217.  https://doi.org/10.1053/j.gastro.2014.10.039.CrossRefPubMedGoogle Scholar
  9. 9.
    Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol. 2009;61(1 Suppl 1):S1–S46.  https://doi.org/10.1016/j.jaad.2009.03.017.CrossRefPubMedGoogle Scholar
  10. 10.
    Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169(6):1295–303.  https://doi.org/10.1111/bjd.12461.CrossRefPubMedGoogle Scholar
  11. 11.
    Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferran M, Garcia-Bustinduy M, Romero-Mate A, Pedragosa R, Garcia-Diez A, Dauden E. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013;168(3):609–16.  https://doi.org/10.1111/bjd.12045.CrossRefPubMedGoogle Scholar
  12. 12.
    Bevans SL, Mayo TT, Elewski BE. Safety of secukinumab in hepatitis B virus. J Eur Acad Dermatol Venereol. 2018;32(3):e120–1.  https://doi.org/10.1111/jdv.14608.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Michael P. Lee
    • 1
  • Kevin K. Wu
    • 2
  • Jashin J. Wu
    • 3
  1. 1.Eastern Virginia Medical SchoolNorfolkUSA
  2. 2.Frank H. Netter MD School of Medicine at Quinnipiac UniversityNorth HavenUSA
  3. 3.Founder and CEODermatology Research and Education FoundationIrvineUSA

Personalised recommendations